Elanco Animal Health Stock Price, News & Analysis

Elanco Animal Health has launched ZoaShield™ in the U.S., a solution for poultry producers to manage coccidiosis effectively. This new product features a proven active ingredient, zoalene, which is vital for maintaining optimal bird health, especially in No Antibiotics Ever (NAE) flocks. Elanco emphasizes that ZoaShield offers producers flexibility to suit various operational needs and seasons. Additionally, the company provides consultative support from experienced field experts, enhancing operational efficiency for poultry producers.

Elanco Animal Health reported strong Q1 2021 results, achieving revenue of $1,242 million, a significant rise from previous guidance of $1,150 - $1,170 million. The addition of Bayer Animal Health contributed $559 million to revenue. Adjusted EPS was $0.37, exceeding expectations. Pet Health revenue surged 213%, while global Seresto sales declined by 9%. Operating expenses were lower than anticipated, enabling Elanco to raise its 2021 guidance for revenue and adjusted EBITDA. The company expects eight product launches to drive future revenue growth.

Elanco Animal Health has launched Credelio Cat, the first oral flea and tick control product for cats, approved by the FDA. This chewable treatment starts killing fleas within 6 hours and provides protection against black-legged ticks for a month. Designed for cats 8 weeks and older, Credelio Cat is palatable and has a high success rate in administration, with 99.5% of owners successfully giving it to their cats. The product joins Elanco's extensive pet health portfolio, addressing a significant market need for effective oral parasite prevention in cats.

On April 28, 2021, Kindred Biosciences (NASDAQ: KIN) announced that the USDA has accepted the efficacy data for its monoclonal antibody, KIND-030, aimed at preventing canine parvovirus (CPV) infection. The pivotal study showed that 0% of treated dogs developed CPV, while the placebo group had a 100% infection rate. This acceptance is a significant milestone, progressing KindredBio's drug development for pets. The company expects to complete the efficacy study for treating established CPV by mid-2021.

Elanco has partnered with Ducks Unlimited to enhance environmental sustainability in beef cattle production across North America. From 2021 to 2023, Elanco will invest $50,000 annually to purchase grass seed for reseeding projects in western Kansas, aiming to restore 1,000 acres through the SAFE initiative. This collaboration aligns with Elanco’s sustainability framework, Healthy Purpose. Additionally, the announcement coincides with the launch of Experior™, a product approved by the FDA to reduce ammonia emissions from cattle waste, underscoring Elanco's commitment to sustainable agriculture.

Elanco Animal Health (NYSE: ELAN) will announce its first quarter 2021 financial results on May 7, 2021. A conference call will follow at 8:00 a.m. ET, accessible to investors, media, and the public via a webcast on Elanco’s website. This event aims to provide detailed insights into the company's performance during the quarter. Elanco is focused on innovating products to improve animal health, with nearly 70 years of experience in the industry.

Elanco Animal Health (NYSE: ELAN) responded to a U.S. House subcommittee request regarding misleading media claims about Seresto collars. The company reaffirms the safety and efficacy of Seresto, stating no recall is warranted. Over 25 million collars have been sold since 2012 with an adverse event rate below 0.3%, primarily non-serious. Elanco collaborates with the subcommittee and emphasizes the lack of scientific basis for a recall. The company underscores its commitment to product safety and continuous monitoring of health data.

Morris Animal Foundation is collaborating with Elanco Animal Health (NYSE: ELAN) to investigate osteoarthritis (OA) in dogs through data from the Golden Retriever Lifetime Study. This study highlights that approximately 14 million adult dogs in the U.S. suffer from OA, often diagnosed in their senior years. Elanco will enhance questionnaires to evaluate OA signs, including walking gait and joint range of motion. The Golden Retriever Lifetime Study is a significant research initiative involving over 3,000 dogs to assess health factors contributing to diseases, including cancer.

Elanco Animal Health Incorporated (NYSE: ELAN) reported its Q4 and full year 2020 financial results, exceeding guidance due to strong performance in U.S. Pet Health and Farm Animal sectors. Revenue reached $1,140 million, surpassing the $1,040 - $1,070 million guidance. Adjusted EPS met expectations, reflecting ongoing productivity efforts. Elanco is optimistic about 2021, raising guidance based on its Innovation, Portfolio, Productivity strategy and solid fundamentals. The company is focused on capturing synergies from the Bayer Animal Health acquisition, enhancing its market position.